Pharming Group N.V. (PHAR) Reports In-Line Q2 EPS

Pharming Group N.V. (NASDAQ: PHAR) reported Q2 EPS of $0.00, in-line with the analyst estimate of $0.00. Revenue for the quarter came in at $74.1 million versus the consensus estimate of $71.94 million.

For earnings history and earnings-related data on Pharming Group N.V. (PHAR) click here.

You May Also Be Interested In

• Calix, Inc. (CALX) Tops Q2 EPS by 6c, Offers Guidance
• Mission Bancorp tops $2 billion in assets as Q2 net income rises
• AdaptHealth to sell diabetes unit to Cardinal Health for $235M